| Catalog No. |
TD-HF869016 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Isotype |
Fusion - [ACVR2B (activin A receptor type 2B, ActR-IIB, ActRIIB)]2 - IGHG1 Fc (Fragment constant) |
| Expression system |
Mammalian Cells |
| Target |
GDF11, BMP-11, BMP11, Growth/differentiation factor 11, GDF-11, Bone morphogenetic protein 11 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
O95390 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
ACE-536,luspatercept–aamt,CAS:1373715-00-4 |
| Background |
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询